Bugworks Research Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
12
Bugworks Research General Information
Description
Developer of a novel class of antibiotic drugs designed to tackle antimicrobial resistance. The company offers a platform that produces multiple broad-spectrum assets and integrates cancer biology and immunology expertise, enabling healthcare providers to overcome efflux-mediated drug resistance and improve treatment outcomes in infectious disease and oncology.
Contact Information
Website
www.bugworksresearch.comCorporate Office
- 2711 Centerville Road
- Suite 400
- Wilmington, DE 19808
- United States
Corporate Office
- 2711 Centerville Road
- Suite 400
- Wilmington, DE 19808
- United States
Bugworks Research Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bugworks Research Comparisons
Industry
Financing
Details
Bugworks Research Competitors (26)
One of Bugworks Research’s 26 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| LEO Pharma | Private Equity-Backed | Ballerup, Denmark | ||||
| F2G | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| 4D pharma | Corporation | Leeds, United Kingdom | ||||
| Venatorx Pharmaceuticals | Venture Capital-Backed | Malvern, PA |
Bugworks Research Patents
Bugworks Research Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025261328-A1 | Indanol substituted diamino pyrimidine carboxamides as dual atm/dna-pk inhibitors | Pending | 23-Apr-2024 | ||
| WO-2025224759-A1 | Indanol substituted diamino pyrimidine carboxamides as dual atm/dna-pk inhibitors | Pending | 23-Apr-2024 | ||
| AU-2025230110-A1 | Triamino pyrimidine compounds as cdk7 inhibitors and methods thereof | Pending | 27-Feb-2024 | ||
| WO-2025181828-A1 | Triamino pyrimidine compounds as cdk7 inhibitors and methods thereof | Pending | 27-Feb-2024 | ||
| EP-4724427-A1 | A process of preparation of an antibacterial compound and its intermediates thereof | Pending | 08-Jun-2023 | C07D498/04 |
Bugworks Research Signals
Bugworks Research Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bugworks Research FAQs
-
When was Bugworks Research founded?
Bugworks Research was founded in 2014.
-
Where is Bugworks Research headquartered?
Bugworks Research is headquartered in Wilmington, DE.
-
What is the size of Bugworks Research?
Bugworks Research has 40 total employees.
-
What industry is Bugworks Research in?
Bugworks Research’s primary industry is Drug Discovery.
-
Is Bugworks Research a private or public company?
Bugworks Research is a Private company.
-
What is Bugworks Research’s current revenue?
The current revenue for Bugworks Research is .
-
How much funding has Bugworks Research raised over time?
Bugworks Research has raised $41.6M.
-
Who are Bugworks Research’s investors?
Featherlite Trailers, Glentec International, , Kotak Alternate Assets Managers, and Lightrock are 5 of 27 investors who have invested in Bugworks Research.
-
Who are Bugworks Research’s competitors?
BioMarin Pharmaceutical, LEO Pharma, F2G, 4D pharma, and Venatorx Pharmaceuticals are some of the 26 competitors of Bugworks Research.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process